A B S T R AC T
Background. Although convective therapies have gained popularity for the optimal removal of uremic solutes, their benefits and potential risks have not been fully elucidated. We conducted a meta-analysis of all randomized controlled trials comparing convective therapies with low-flux hemodialysis in patients with chronic kidney failure. Methods. We performed a literature search using MEDLINE (inception-December 2012), Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, scientific abstracts from meetings and bibliographies of retrieved articles. Randomized controlled trials comparing the effect of convective therapies including high-flux hemodialysis, hemofiltration or hemodiafiltration versus low-flux hemodialysis were included. Random-effects model meta-analyses were used to examine continuous and binary outcomes. Results. Sixty-five (29 crossover and 36 parallel-arm) trials were identified (n = 12 182). Convective therapies resulted in a decrease in all-cause mortality [relative risk (RR) 0.88; 95% confidence interval (CI) 0.76, 1.02, P = 0.09], cardiovascular mortality (RR 0.84; 95% CI 0.71, 0.98, P = 0.03), all-cause hospitalization (RR 0.91; 95% CI 0.82, 1.01; P = 0.08) and therapy-related hypotension (RR 0.55, 95% CI 0.35, 0.87, P = 0.01). Convective therapies also resulted in an increase in the clearance of several low-molecular-weight (urea, creatinine and phosphate), middle-sized (β-2 microglobulin and leptin) and protein-bound (homocysteine, advanced glycation endproducts and pentosidine) solutes and a decrease in inflammatory markers (interleukin-6). There was no impact of convective therapies on cardiac morphological and functional parameters, and blood pressure and anemia parameters. Conclusions. Although convective therapies are associated with improved clearance of uremic solutes, the potential longterm benefits of specific convective modalities require further study.
I N T R O D U C T I O N
Cardiovascular disease is the leading cause of death in patients with chronic kidney failure treated by hemodialysis [1, 2] . Among the many cardiovascular risk factors [3] , retained uremic toxins have gained their place as potential contributors to cardiovascular morbidity, and as a result, there is an ongoing quest to optimize their removal. Uremic toxins are classified into free water-soluble low-molecular-weight solutes (e.g. urea and creatinine), middle-sized solutes (e.g. β2-microglobulin) and protein-bound solutes (e.g. p-cresol) [4] . Conventional low-flux hemodialysis provides diffusive clearance of low-molecular-weight solutes with limited ability to remove middle-sized solutes [5] . In contrast, convective therapies, including hemofiltration, hemodiafiltration and high-flux hemodialysis, provide higher clearance of middle-sized solutes, and might offer superior clinical benefits compared with low-flux hemodialysis [6, 7] . A prior meta-analysis of 20 studies totaling 657 patients published in 2006 failed to demonstrate any clinical benefit of convective therapies compared with hemodialysis in terms of decreased mortality, hospitalization and treatment-related hypotension [8] . Several trials of convective therapies have since been completed [9] , including the highprofile Membrane Permeability Outcome (MPO) Study [10] and the Convective Transport Study (CONTRAST) [11] . To provide an update on this topic, we conducted a meta-analysis of all randomized controlled trials published to date that examined the efficacy and safety of convective therapies compared with low-flux hemodialysis.
M E T H O D S

Data sources and searches
We performed a MEDLINE literature search (inception-December 2012) to identify eligible studies using the Medical Subject Headings (MeSH) search terms 'uremic toxin', 'convective therapy', 'convection', 'high-flux hemodialysis', 'hemofiltration'. 'hemodiafiltration', 'low-flux hemodialysis' or 'conventional hemodialysis' (Supplemental Table S1 ). The search was limited to human studies. We also searched the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for completed studies using similar search terms, and reviewed the American Society of Nephrology scientific abstracts (2003-2012 meetings) , as well as the bibliographies of retrieved articles.
Study selection and outcomes of interest
We included crossover and parallel-arm randomized controlled trials comparing the effects of convective therapies, including high-flux hemodialysis, hemofiltration or hemodiafiltration versus low-flux hemodialysis on all-cause and cause-specific mortality, hospitalization, treatment-related hypotension and several surrogate endpoints; these included circulating levels and/or removal of uremic solutes, serum electrolytes, inflammatory markers, anemia parameters (hemoglobin, hematocrit, transferrin, ferritin, transferrin saturation, dose of intravenous iron and erythropoietin resistance index), nutritional parameters (body weight, serum albumin, normalized protein catabolic rate and lipid profile), blood pressure parameters (systolic and diastolic blood pressure, mean arterial pressure, therapy-related hypotension and number of prescribed anti-hypertensive medications), cardiac morphological and functional parameters and residual kidney function (calculated glomerular filtration rate derived from the mean of creatinine and urea clearance or iohexol clearance). There were no restrictions on language, sample size or study duration. Duplicate studies were excluded. However, if authors published more than one paper on the same study, data from the most inclusive report were used. Two authors (P.S. and M.S.) independently screened the titles and abstracts of all electronic citations, and full-text articles were retrieved for a comprehensive review and independently re-screened.
Data extraction and quality assessment
The following study characteristics were extracted: country of origin, year of publication, study design, sample size, treatment modality, duration of intervention (in months), mean age, dialysis duration, percentage of men and percentage of patients with diabetes mellitus, hypertension and cardiovascular disease. Uremic toxins were grouped according to the European Uremic Toxin Work Group classification, including water-soluble low molecular weight (<500 Da) solutes, middle-sized (>500 Da) solutes and protein-bound solutes [12] . Data on the afore mentioned study endpoints were extracted, including the number of patients with and without the binary outcomes of interest, and the absolute difference in means of continuous variables in each study arm. When indicated, the G3data graph analyzer (version 1.5.3; GNU General Public License, www.frantz.fi/software/ g3data.php) was used to extract data from graphs. Disagreements were resolved by consensus. Study quality was assessed using the Jadad scale with higher scores reflecting better quality [13] .
Data synthesis and analysis Random-effects model meta-analyses were used to compute absolute net changes in mean values of continuous outcomes, and relative risks (RRs) for binary outcomes. Analyses of binary outcomes were restricted to the parallel-arm trials. For the analyses of continuous outcomes, parallel-arm and crossover trials were grouped together but were also analyzed separately. All pooled estimates are displayed with a 95% confidence interval (CI).
Existence of heterogeneity among study effect sizes was examined using the I 2 index and the Q-test P value. An I 2 index of ≥50% was used to indicate medium-to-high heterogeneity [14] . When present, heterogeneity was investigated by performing subgroup analyses according to certain study characteristics, including trial design (crossover versus parallel-arm), treatment modality (high-flux hemodialysis, hemofiltration versus hemodiafiltration), duration of follow-up (1-6, 7-12 versus >12 months) and study quality (fair versus good). The Student t-test was used to compare subgroups. Publication bias was formally assessed using funnel plots and the Egger test [15] . All analyses were performed using Comprehensive Meta-Analysis version 2.0 (Biostat, www.meta-analysis.com). Figures for the subgroup analyses were generated using the R system software version 2.13.0 (cran.rproject.org/bin/windows/base/old/ 2.13.0).
R E S U LT S
Characteristics and quality of the studies A total of 17 946 potentially relevant citations were identified and screened. Two hundred and ninety-one articles were retrieved for detailed evaluation, of which 65 fulfilled eligibility criteria comprising 29 crossover and 36 parallel-arm randomized controlled trials [9] [10] [11] (Figure 1 ). Eight trials had two different convective treatment groups [19, 25, 36, 37, 42, 57, 71, 73] , and three trials had three different convective treatment groups [43, 47, 54] (Table 1) . One trial reported separately on two different outcomes [41, 50] . Three studies were post hoc analyses from the HEMO Study examining different endpoints [35, 48, 56] . Three reports were either ancillary studies or represented a post hoc analysis of the CONTRAST trial [66, 69, 70] . One study was a post hoc analysis [65] of a previously published trial of hemofiltration [51] .
Characteristics of the individual trials are displayed in Table 1 . The trials spanned >20 years, varied in sample size (6-1846 patients) and involved one of three convective therapies, high-flux hemodialysis (42 treatment arms), hemofiltration (10 treatment arms) and hemodiafiltration (27 treatment arms). The mean age ranged from 19 to 83 years, and duration of follow-up from 4 to 380 months. Thirty-five studies (54%) were considered of fair quality (Scores 1 and 2) and 30 studies (46%) of good quality (Scores 3-5).
Effect of convective therapies on mortality and hospitalization As shown in Table 2 , by meta-analysis, compared with lowflux hemodialysis, convective therapies resulted in a decrease of all-cause mortality ( pooled RR 0.88; 95% CI 0.76, 1.02, P = 0.09; I 2 index = 18%; Q-test P = 0.22), cardiovascular mortality ( pooled RR 0.84; 95% CI 0.71, 0.98, P = 0.03; I 2 index = 0%; Q-test P = 0.97), all-cause hospitalization ( pooled RR 0.91; 95% CI 0.82, 1.01; P = 0.08; I 2 index = 78%; Q-test P < 0.001) and therapy-related hypotension ( pooled RR 0.55, 95% CI 0.35, 0.87, P = 0.01; I 2 index = 99%; Q-test P < 0.001). Convective therapies had no impact on infection-related mortality.
Effect of convective therapies on uremic solutes
As shown in Table 3 , by meta-analysis, convective therapies improved the clearance of several low-molecular-weight solutes. Indeed, there was a significant net increase in the clearance of urea by 23.4 mL/min (95% CI 7.3, 39.6; P = 0.01), creatinine by 19.6 mL/min (95% CI 11.9, 27.4, P < 0.001) and phosphate by 20.8 mL/min (95% CI 12.3, 29.2, P < 0.001). There was also an 8.6% net increase in the phosphate reduction ratio (95% CI 5.5, 11.7, P < 0.001).
Similar results were observed for the removal of middlesized and protein-bound solutes (Table 3) , with a 64.8 mL/ min net increase in β2-microglobulin clearance (95% CI 46.8, 82.8; P < 0.001), a 60.8% net increase in the β2-microglobulin reduction ratio (95% CI 51.1, 70.5; P < 0.001), and a 205 mg net increase in β2-microglobulin removal per session (95% CI 154, 256; P < 0.001). Convective therapies resulted in a significant net increase in the reduction ratio of homocysteine (P = 0.002), leptin (P < 0.001) and advanced glycation endproducts (P < 0.001) ( Table 3 ). There was also a significant net decrease in pre-therapy serum levels of β2-microglobulin (−9.94 mg/dL; 95% Cl −12.42, −7.46, P < 0.001), homocysteine (−1.97 mg/dL; 95% CI −3.67, −0.27, P = 0.02) and pentosidine (P ≤ 0.001). 
O R I G I N A L A R T I C L E
M e t a -a n a l y s i s o f c o n v e c t i v e t h e r a p i e s 
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O R I G I N A L A R T I C L E
M e t a -a n a l y s i s o f c o n v e c t i v e t h e r a p i e s Convective therapies had no significant impact on pretherapy serum levels of other solutes, including uric acid, leptin, asymmetric dimethylarginine, vitamin B12, parathyroid hormone, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid, indole acetic acid, indoxyl sulfate, hippuric acid and advanced oxidation protein products.
Effect of convective therapies on cardiac morphology and function, and blood pressure parameters By meta-analysis, convective therapies had no significant effect on measures of cardiac morphology and function relative to low-flux hemodialysis, including net changes in left ventricular mass index, left ventricular end-systolic and enddiastolic diameter, posterior wall diameter, ejection fraction, fractional shortening of the left ventricular diameter, stroke volume and pulse-wave velocity (Table 4) .
Similarly, by meta-analysis, relative to low-flux hemodialysis, convective therapies had no significant effect on net changes in systolic or diastolic blood pressure, mean arterial pressure, pulse rate and number of prescribed anti-hypertensive medications (Table 4) .
Effect of convective therapies on anemia and nutritional parameters Convective therapies had no significant impact on any of the anemia parameters, including net changes in hemoglobin, hematocrit, transferrin, ferritin, transferrin saturation, dose of intravenous iron and erythropoietin resistance index (Table 4) .
In terms of nutritional parameters, convective therapies resulted in a net increase in body weight of 0.68 kg (95% CI 0.33, 1.02; P < 0.001), and the pre-therapy serum high-density lipoprotein cholesterol level of 3.87 mg/dL (95% CI 0.93, 6.81; P = 0.01). In contrast, convective therapies resulted in a net decrease in the pre-therapy serum albumin level of 0.04 g/dL (95% CI −0.08, −0.01; P = 0.03), and triglycerides of 20.25 mg/dL (95% CI −32.60, −7.91; P = 0.001). There were no noticeable effects on other nutritional parameters, including normalized protein catabolic rate, and total cholesterol and lowdensity lipoprotein cholesterol levels ( Table 4) .
Effect of convective therapies on inflammatory markers and other parameters
By meta-analysis, convective therapies resulted in a significant 0.42 pg/mL net decrease in pre-therapy serum interleukin-6 level (95% CI −0.73, −0.11; P = 0.01) and superoxide dismutase (P = 0.03). There were no noticeable effects on other inflammatory markers, including C-reactive protein and total antioxidant capacity (Table 4) .
Convective therapies resulted in a significant net decrease in pre-dialysis serum calcium level of 0.02 mg/dL (95%CI −0.036, −0.003, P = 0.02), which is of unclear significance. There was no effect of convective therapies on residual kidney function and pre-therapy serum electrolyte levels relative to low-flux hemodialysis (Table 4) . Figures 2-4 display the results of subgroup analyses exploring the pooled RR for all-cause mortality and therapy-related hypotension and absolute net changes in pre-therapy serum levels of β2-microglobulin, stratified by modality type, duration of follow-up and study quality. In brief, a lower RR for all-cause mortality was observed in studies of longer duration (>12 months) and of fair quality (Figure 2) . Similarly, a lower pooled RR for therapy-related hypotension was observed in 
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M e t a -a n a l y s i s o f c o n v e c t i v e t h e r a p i e s studies that employed hemofiltration and studies of longer duration (>12 months) and of fair quality (Figure 3) . A significant pooled net decrease in pre-therapy serum β2-microglobulin level was observed in all subgroups, except for studies of mid-range (7-12 months) duration (Figure 4) . In a sensitivity analysis, after excluding two trials that used super high-flux dialyzers that are permeable to large-sized proteins [36, 46] , convective therapies were no longer associated with a 
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O R I G I N A L A R T I C L E
M e t a -a n a l y s i s o f c o n v e c t i v e t h e r a p i e s significant net decrease in serum albumin (−0.02 g/dL; 95%CI −0.06, 0.02, P = 0.23). Similar trends were observed in all of the meta-analyses of continuous outcomes that were restricted to either crossover or parallel-arm trials (Supplemental Tables  S2-S5) . Funnel plots for the main outcomes of interest were symmetric and the Egger test was not significant (P > 0.05), suggesting less susceptibility to publication bias. Tables 3 and  4 provide the Egger test P value for the secondary outcomes of interest.
D I S C U S S I O N
In the present meta-analysis of randomized controlled trials, we demonstrate that convective therapies, as defined by the use of high-flux hemodialysis, hemofiltration or hemodiafiltration, are associated with a near significant decrease in all-cause mortality, but a significant decrease in cardiovascular mortality and therapy-related hypotension compared with low-flux hemodialysis. Convective therapies were also associated with a significant net increase in the removal of several uremic toxins, including middle-sized and protein-bound solutes such as β2-microglobulin and homocysteine. In addition, convective therapies resulted in a net decrease in circulating markers of inflammation such as interleukin-6. Of note, while convective therapies resulted in a net increase in patient body weight, there was a net decrease in serum albumin. This latter observation was reversed in analyses that excluded trials that used super high-flux dialyzers that are permeable to large-sized proteins. There was no demonstrable benefit of convective therapies on cardiovascular surrogate endpoints, including changes in measures of cardiac morphology and function or blood pressure parameters, as well as anemia-related parameters.
Worldwide, hemodialysis is the most commonly used treatment modality for chronic kidney failure. While clinical practice guidelines for adequacy of hemodialysis have traditionally focused on the removal of small molecular-weight solutes [78] , annual mortality rates of patients with chronic kidney failure treated by conventional hemodialysis have remained alarmingly high [2] . This implies that the delivery of hemodialysis in its current most prevalent form is suboptimal and has failed to further improve patient outcomes [32] . Technological advances in the provision of dialysis, including the now widespread adoption of high-flux dialyzers for delivering high-flux hemodialysis, as well as chronic hemofiltration and hemodiafiltration have been gaining popularity [6, 10] , with the perceived notion that these therapies might enhance the removal of large uremic toxins and improve clinical outcomes.
Our analysis demonstrating a trend toward a survival benefit of convective therapies over low-flux hemodialysis and that included 22 trials (4848 patients), contrasts with a previous meta-analysis of 20 studies (657 patients) published in 2006, which showed no survival benefit [8] . Methodological differences account for the discrepancy, mainly the definition of convective therapies, which in our analysis, included highflux hemodialysis, both a diffusive and convective therapy, as well as the addition of two large trials of combined diffusive and convective therapies [10, 11] . The enhanced removal of β2-microglobulin by convective therapies observed in our meta-analysis coupled to the trend in the observed patient survival benefit is consistent with a post hoc analysis from the HEMO study demonstrating an association between lower pre-dialysis serum β2-microglobulin levels and greater patient survival [56] .
Cardiovascular disease, the leading cause of death among patients with chronic kidney failure [2] , is partly driven by a plethora of traditional risk factors such as hypertension, diabetes and hyperlipidemia, as well as nontraditional uremiarelated factors that are unique to this patient population, such as hyper-homocysteinemia [79] . In a post hoc analysis from the HEMO trial, high-flux hemodialysiswas associated with fewer cardiac deaths and a lower composite outcome of first cardiac hospitalization or cardiac death [35] . These observations are replicated in the present meta-analysis with a lower cardiovascular mortality and therapy-related hypotension. In addition, several cardiovascular risk factors and risk markers were favorably modified by convective therapies, including a net decrease in pre-dialysis serum levels of homocysteine, triglycerides and interleukin-6, as well as a net increase in the pre-dialysis high-density lipoprotein cholesterol level. The inconclusive results on the effect of convective therapies on cardiac structural and functional parameters might be due in part to the small sample size of the studies included in the analyses of these endpoints. The malnutrition-inflammation score, which entails serum albumin, has been shown to independently predict 5-year mortality in patients receiving hemodialysis [80] . In one trial, high-flux hemodialysis conferred better survival among patients with low serum albumin levels (<4 g/dL) [10] . In our analysis, while the baseline pre-dialysis pooled serum albumin level was 3.89 g/dL, convective therapies resulted in a net increase in body weight, but there was a net decrease in serum albumin. While the latter finding became non-significant in a sensitivity analysis, the potential benefit of convective therapies on nutritional parameters requires further examination.
Strengths of our synthesis include the large number of trials, and the demonstrable benefit of convective therapies on mortality, hospitalization and therapy-related hypotension. In addition, we observed an improvement in several surrogate endpoints, including the removal of small, middle and large molecular-weight solutes, increase in body weight and decrease in some inflammatory markers. However, we were unable to demonstrate a benefit on cardiac structure and function, systolic and diastolic blood pressure and anemia parameters. There are several limitations that should be emphasized. We defined convective therapies as the use of hemofiltration, hemodiafiltration and high-flux hemodialysis. In doing so, we combined pure convective with both diffusive and convective therapies, which might account for some of the observed heterogeneity in the effect estimates of individual studies. Finally, we were unable to explore other potential confounding factors such as dialyzer reuse practices, frequency, duration and delivered dose of the convective therapy, and water purity.
In conclusion, convective therapies, including high-flux hemodialysis, hemofiltration and hemodiafiltration are associated with an increase in the removal of several uremic solutes and inflammatory markers relative to low-flux hemodialysis. These changes might confer a long-term survival benefit in terms of a decline in all-cause and cardiovascular mortality and a decrease in hospitalizations and therapy-related hypotension. These findings call for the design of large multicenter randomized controlled trials of convective therapies aimed at exploring their potential impact on these hard clinical endpoints as well as on other surrogate endpoints such as proteinbound uremic toxins, cardiac structure and function, and nutritional and inflammatory markers, with the ultimate goal of informing clinical practice. 
